Does stage III chronic kidney disease always progress to end-stage renal disease? A ten-year follow-up study

Baek, Seung Don; Baek, Chung Hee; Kim, Ja Seon; Kim, So Mi; Kim, Ji Hyun; Kim, Soon Bae

doi:10.3109/00365599.2011.649045

Cited by 46 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…it is a late marker of disease progression. Moreover, many CKD patients in the G3a category 1,7 , the most prevalent CKD category, never progress, as recently observed for a classical albuminuric disease such as diabetic nephropathy. Although UAE is clinically useful to stratify risk, in some patients there are discrepancies between the urinary albumin creatinine ratio and 24h UAE 8 .…”

Section: Introductionmentioning

confidence: 63%

Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease

Rodríguez‐Ortiz

Pontillo

Rodríguez

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Chronic kidney disease is associated with increased risk of CKD progression and death. Therapeutic approaches to limit progression are limited. Developing tools for the early identification of those individuals most likely to progress will allow enriching clinical trials in high risk early CKD patients. The CKD273 classifier is a panel of 273 urinary peptides that enables early detection of CKD and prognosis of progression. We have generated urine capillary electrophoresis-mass spectrometry-based peptidomics CKD273 subclassifiers specific for CKD stages to allow the early identification of patients at high risk of CKD progression. In the validation cohort, the CKD273 subclassifiers outperformed albuminuria and CKD273 classifier for predicting rapid loss of eGFR in individuals with baseline eGFR > 60 ml/min/1.73 m2. In individuals with eGFR > 60 ml/min/1.73 m2 and albuminuria <30 mg/day, the CKD273 subclassifiers predicted rapid eGFR loss with AUC ranging from 0.797 (0.743–0.844) to 0.736 (0.689–0.780). The association between CKD273 subclassifiers and rapid progression remained significant after adjustment for age, sex, albuminuria, DM, baseline eGFR, and systolic blood pressure. Urinary peptidomics CKD273 subclassifiers outperformed albuminuria and CKD273 classifier for predicting the risk of rapid CKD progression in individuals with eGFR > 60 ml/min/1.73 m2. These CKD273 subclassifiers represented the earliest evidence of rapidly progressive CKD in non-albuminuric individuals with preserved renal function.

show abstract

Section: Introductionmentioning

confidence: 63%

Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease

Rodríguez‐Ortiz

Pontillo

Rodríguez

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…A systematic review has shown that the mortality rate of the patients with Stage 3 CKD is higher than those without CKD [28]. Another review has shown that half of the patients suffering from Stage 3 CKD have progressed to Stage 4 and Stage 5 over 10 years [29]. Eventually, these patients will need renal replacement therapy and kidney transplantation in near future.…”

Section: Discussionmentioning

confidence: 99%

Detection of Chronic Kidney Disease by Using Different Equations of Glomerular Filtration Rate in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Analysis

Zaman

2017

Cureus

View full text Add to dashboard Cite

IntroductionChronic kidney disease (CKD) is a global threat due to its high mortality. It is essential to know the actual magnitude of diabetic CKD to design a specific management program. However, there is limited knowledge regarding the most suitable equation to measure CKD in patients with Type 2 diabetes mellitus (T2DM). This paper aimed to analyze estimated glomerular filtration rate (eGFR) based on different equations to detect the CKD among T2DM. MethodsA hospital-based cross-sectional study was carried out, and a clinical registry was used to collect 4,042 T2DM patients from a large district hospital in Northeast Thailand. CKD patients were diagnosed when eGFR was less than 60 ml/min/1.73m2. Using Stata statistical software (StataCorp LP, College Station, TX), three standard equations, such as ‘modification of diet in renal disease (MDRD-4)’, ‘chronic kidney disease epidemiology collaboration (CKD-EPI)’, and ‘Cockcroft-Gault (C-G)' equations, were used to produce eGFR values to report and compare stages of CKD.ResultsThe mean age of the patients was 61.4 (± 10.7) years and male to female ratio was 1:1.9. According to the MDRD-4, CKD-EPI, and C-G equation, the prevalence of diabetic CKD was 21.4%, 21.9%, and 31.4%, respectively, and the frequency of CKD Stage 3 to 5 was found to be different among T2DM. About 3,789 (93.9%) measurements appeared to be classified as different stages of CKD (Stages 1 to 5) between MDRD-4 and CKD-EPI equations (kappa: 0.905; 95% confidence interval (CI): 0.83 - 0.97, p < 0.001). However, this study found that the above-mentioned agreement was 70.9% between CKD-EPI and C-G equation (kappa: 0.56, 95% CI: 0.44 - 0.67, p < 0.001).ConclusionsCKD-EPI equations can overcome the constraint of MDRD-4 and C-G equations to report CKD and can be used in patients with T2DM.

show abstract

“…Biomarkers including an abnormal ankle-brachial index (ABI), arterial stiffness, increased common carotid artery (CCA) diameter and intima-media thickness (CIMT), and left ventricular hypertrophy (LVH) are associated with increased cardiovascular risks and worse prognosis in CKD (Szeto et al, 2007;Chue et al, 2010;Paoletti et al, 2011;Karras et al, 2012;Kozakova et al, 2017;Chen et al, 2017;Major et al, 2018). Moreover, most of the studies of mildto-moderate CKD have evaluated the deterioration of renal function over time (Baek et al, 2012;Hallan et al, 2012), and few have addressed the longitudinal changes in biomarkers associated with cardiovascular risk (Seifert et al, 2014;Agarwal, 2017). Moreover, most of the studies of mildto-moderate CKD have evaluated the deterioration of renal function over time (Baek et al, 2012;Hallan et al, 2012), and few have addressed the longitudinal changes in biomarkers associated with cardiovascular risk (Seifert et al, 2014;Agarwal, 2017).…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular changes in patients with mild‐to‐moderate chronic kidney disease compared with healthy subjects: a 5‐year follow‐up study

Anna¹,

Wallquist²,

Rickenlund³

et al. 2019

Clin Physio Funct Imaging

View full text Add to dashboard Cite

Background There is limited knowledge about how cardiovascular parameters change over time in patients with mild-to-moderate chronic kidney disease (CKD). We studied several cardiovascular biomarkers over a 5-year period in patients with mild-to-moderate CKD and in healthy controls. Methods Fifty-four patients with CKD stages 2-3 and 54 controls were included. The CKD patients were closely monitored and well controlled for hypertension and other cardiovascular risk factors. Ambulatory blood pressure (BP) monitoring, ankle-brachial index (ABI), carotid and cardiac ultrasound (including measurement of the left ventricular mass index (LVMI)), and biochemical analyses were evaluated. Results Renal function decreased in both groups, with no significant difference in the change over time. In the CKD patients, none of the BP variables increased over time, but in the controls, average 24-h and daytime systolic BP increased significantly. ABI increased slightly in the CKD patients (P<0Á001), but not in the controls (P = 0Á963), and phosphate had a significant positive effect on ABI. Although in the CKD patients, there was no significant increase over time in common carotid artery diameter (P = 0Á274), there was a small but significant increase in the controls (P = 0Á001). LVMI increased significantly over time in both groups. Conclusions In our study of patients with mild-to-moderate CKD, the progression of cardiovascular changes over time was relatively slow. Good BP control and treatment of other risk factors may have contributed to slow the progress of cardiovascular involvement, which emphasizes the importance of dedicated care in this population.

show abstract

Does stage III chronic kidney disease always progress to end-stage renal disease? A ten-year follow-up study

Cited by 46 publications

References 23 publications

Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease

Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease

Detection of Chronic Kidney Disease by Using Different Equations of Glomerular Filtration Rate in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Analysis

Cardiovascular changes in patients with mild‐to‐moderate chronic kidney disease compared with healthy subjects: a 5‐year follow‐up study

Contact Info

Product

Resources

About